Abbonarsi

Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate - 19/03/21

Doi : 10.1016/j.biopha.2021.111373 
Jiali Zhu, Tao Yang, Minghai Tang, Zhuang Yang, Heying Pei, Haoyu Ye, Yu Tang, Zhixuan Cheng, Ping Lin, Lijuan Chen
 State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 15
Iconografia 10
Video 0
Altro 0

Abstract

Psoriasis is a chronic, inflammatory autoimmune disease mediated by T cells, and characterized with abnormal proliferation and differentiation of keratinocytes, and inflammatory infiltration. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway has been identified to play essential roles in mediating various of biological processes, and is closely related to autoimmune diseases. Dendritic cells (DCs) are important antigen presenting cells and play an important regulatory role in T cells. The proliferation, differentiation and function of DCs are regulated by JAK and FMS-like tyrosine kinase 3 (FLT3) signal pathways. Flonoltinib maleate (FM), a high selectivity dual JAK2/FLT3 inhibitor with IC50 values of 0.8 nM and 15 nM for JAK2 and FLT3, respectively, was developed by our laboratory. Moreover, FM was a potent JAK2 inhibitor with 863-fold and 696-fold selectivity over JAK1 and JAK3, respectively. In this study, the anti-psoriasis activity of FM was evaluated both in vitro and in vivo. FM effectively inhibited the proliferation of HaCaT, the inflammatory keratinocyte induced by M5 and markedly suppressed the generation and differentiation of DCs from bone marrow (BM), and inhibited the expression of FLT3 in DCs in vitro. FM effectively inhibited the ear thickening and improved the pathological changes of the ear in interleukin (IL)-23-induced psoriasis-like acanthosis mouse model. Further in keratin 14-vascular endothelial growth factor (K14-VEGF) transgenic homozygous mice model, FM could obviously improve the psoriatic symptom and pathological changes, significantly inhibit the generations of Th1 and Th17 cells in the spleen, and the accumulations of DCs in the ears. FM could also significantly reduce the expression of various inflammatory factors both in C57BL/6 and K14-VEGF mice ears, and the serum of K14-VEGF mice. Mechanism revealed that FM effectively suppressed the phosphorylation of JAK2, STAT3 and STAT5 in inflammatory keratinocytes and the mice ears of C57BL/6 and K14-VEGF, as well as the phosphorylation of FLT3 in K14-VEGF mice ears. In conclusion, FM plays an excellent anti-psoriasis activity, including inhibiting keratinocyte proliferation and regulating inflammatory response through inhibiting JAK2 and FLT3 signaling pathway.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




ga1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Flonoltinib maleate (FM), a high selectivity dual JAK2/FLT3 inhibitor.
FM could effectively suppress the generation and differentiation of DCs from BMDCs, and inhibit FLT3 expression of DCs in vitro.
FM could effectively alleviate psoriasis in IL-23-induced psoriasis-like acanthosis mice and K14-VEGF transgenic mice.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : DCs, IL, IFN, TNF, JAK-STAT, TYK2, FLT3, FM, NMPA, K14-VEGF, SPF, OSM, DMSO, BM, rhFLT3L, PBS, NS, PASI, ELISA, BMDCs, pDCs, mDCs, HE, LSD

Keywords : Psoriasis, Flonoltinib maleate (FM), JAK-STAT signal pathway, DCs, FLT3, Inflammation


Mappa


© 2021  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 137

Articolo 111373- maggio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation
  • Lin Ye, Xueting Hu, Xiang Hu, Sihui Yin, Jianqiang Chen, Hanghui He, Shanshan Hong, Bin Yang, Krishna K. Singh, Jianpeng Feng, Yi Wang, Wu Luo, Guang Liang
| Articolo seguente Articolo seguente
  • Therapeutic monitoring of carbamazepine and its active metabolite during the 1st postnatal month: Influence of drug interactions
  • Ivana Kacirova, Milan Grundmann, Hana Brozmanova

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.